呼吸器感染症に対するBRL25000(Clavulanic acid Amoxicillin)の臨床的検討 (BRL25000(Clavulanic acid-Amoxicillin)<特集>)

概要

論文の詳細を見る
Nine chronic bronchitic patients with either pneumoconiosis, hypothyroidism and diabetes mellitus, or syphylis and lung fibrosis and a previous long medical and therapeutic history (ages; 50-59 years 2 cases, 60-69 years 4 cases, 70-79 years 3 cases, sexes; male 8, female 1), and one patient with chronic panbronchiolitis (41 years, male) and another with moderate to severe acute bronchitis (31 years, female), were included in the study. In all 20 courses of therapy with BRL 25000 were studied in a total of 11 patients. The dosages (total in g.) and duration of therapy were as follows; one tablet, three times a day, after meals, 7 or 8 days (7.875-9.0g): 10 cases, 14 days (15.75g) 1 case, one tablet, four times a day, after meals and before sleep (10.5g): 2 cases, two tablets, three times a day, after meals, 7 days (15.75g): 1 case, 14 days (31.5g): 4 cases, 21 days (47.25g) and 28 days (63.0g) in each one case.<BR>Clinically excellent results were obtained and the overall clinical effectiveness rate was 73.7%(14/19), the bacteriological eradication rate from sputum was 52.9%(9/17). No side effects and abnormal clinical findings were found.
公益社団法人日本化学療法学会の論文